- Stacy Enxing Seng Joins the Vesper Medical Board of Directors
Wayne, PA, January 4, 2021 Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated - Read More >>
- Vesper Medical Announces First Enrollment in the VIVID Trial
Malvern, PA, December 1, 2020 Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced initiation of its U.S. Food and Drug Administration (FDA) Investigational Exemption (IDE) study – Venous stent for the Iliofemoral Vein Investigational clinical trial using the Vesper DUO Venous Stent System® (VIVID). The VIVID Trial, which - Read More >>
- Vesper Medical Announces $37 Million Financing with Vensana Capital and Gilde Healthcare to Complete Development of its Duo Venous Stent System™
May 29, 2019- WAYNE, Pa.–(BUSINESS WIRE)– Vesper Medical, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced a $37 million financing with Vensana Capital and Gilde Healthcare as lead investors. - Read More >>
